<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03891979</url>
  </required_header>
  <id_info>
    <org_study_id>18-00137</org_study_id>
    <nct_id>NCT03891979</nct_id>
  </id_info>
  <brief_title>Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma</brief_title>
  <official_title>A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-institutional, single arm pilot study of antibiotics and pembrolizumab for the&#xD;
      treatment of surgically resectable pancreatic cancer. The primary purpose of this study is to&#xD;
      determine the change in immune activation in pancreatic tumor tissue following treatment with&#xD;
      antibiotics and pembrolizumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Suspended due to Primary Investigator's decision&#xD;
  </why_stopped>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in immune activation in pancreatic tumor tissue following treatment with antibiotics and pembrolizumab measured by activation of HLA-DR,</measure>
    <time_frame>12 Weeks</time_frame>
    <description>activation is defined as an increase of 20% or more over baseline in percentage of T cells expressing the marker.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in immune activation in pancreatic tumor tissue following treatment with antibiotics and pembrolizumab measured by activation of</measure>
    <time_frame>12 Weeks</time_frame>
    <description>activation is defined as an increase of 20% or more over baseline in percentage of T cells expressing the marker.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + Antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.&#xD;
Ciprofloxacin 500mg PO BID days 1-29; Metronidazole 500mg PO TID days 1-29; Pembrolizumab 200mg IV days 8 and 29.</description>
    <arm_group_label>Pembrolizumab + Antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin 500mg PO BID days 1-29</intervention_name>
    <description>Antibiotics will continue throughout the entire four week pre-operative period.</description>
    <arm_group_label>Pembrolizumab + Antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole 500mg PO TID days 1-29</intervention_name>
    <description>Antibiotics will continue throughout the entire four week pre-operative period.</description>
    <arm_group_label>Pembrolizumab + Antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed pancreatic adenocarcinoma. Histologies other than&#xD;
             adenocarcinoma, or any mixed histologies, will NOT be eligible. *Note: histology must&#xD;
             be confirmed prior to study treatment, however, participants may be consented to study&#xD;
             based on imaging results consistent with pancreatic adenocarcinoma and then undergo&#xD;
             diagnostic and research biopsy simultaneously.&#xD;
&#xD;
          -  Clinical stage I and II disease (per AJCC 8th ed)&#xD;
&#xD;
          -  Resectable pancreatic cancer as defined by NCCN Guidelines 1.2018 and based on&#xD;
             pancreatic protocol dual-phase CT imaging. Multi-detector computed tomography (MDCT)&#xD;
             angiography, performed by acquiring thin, preferably sub-millimeter, axial sections&#xD;
             using a dual-phase pancreatic protocol, with images obtained in the pancreatic and&#xD;
             portal venous phase of contrast enhancement, is required.&#xD;
&#xD;
          -  No arterial tumor contact (celiac axis [CA], superior mesenteric artery [SMA], or&#xD;
             common hepatic artery [CHA])&#xD;
&#xD;
          -  No tumor contact with the superior mesenteric vein (SMV) or portal vein (PV) or ≤180°&#xD;
             contact without vein contour irregularity&#xD;
&#xD;
          -  Patients must agree to pre-treatment biopsy and definitive surgical resection&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  No prior treatment for diagnosis of pancreatic cancer&#xD;
&#xD;
          -  Normal organ and marrow function&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1500/µL&#xD;
&#xD;
          -  Platelets ≥100 000/µL&#xD;
&#xD;
          -  Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/La&#xD;
&#xD;
          -  Renal Creatinine OR Measured or calculated by creatinine clearance (GFR can also be&#xD;
             used in place of creatinine or CrCl) ≤1.5 × ULN OR&#xD;
&#xD;
             ≥30 mL/min for participant with creatinine levels &gt;1.5 × institutional ULN&#xD;
&#xD;
          -  Hepatic Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total&#xD;
             bilirubin levels &gt;1.5 × ULN&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) ≤2.5 × ULN&#xD;
&#xD;
          -  Coagulation International normalized ratio (INR) OR prothrombin time (PT)&#xD;
&#xD;
          -  Activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless participant is&#xD;
             receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of&#xD;
             intended use of anticoagulants&#xD;
&#xD;
          -  ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST&#xD;
             (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase);&#xD;
             GFR=glomerular filtration rate; ULN=upper limit of normal.&#xD;
&#xD;
          -  Criteria must be met without erythropoietin dependency and without packed red blood&#xD;
             cell (pRBC) transfusion within last 2 weeks.&#xD;
&#xD;
          -  Creatinine clearance (CrCl) should be calculated per institutional standard. Note:&#xD;
             This table includes eligibility-defining laboratory value requirements for treatment;&#xD;
             laboratory value requirements should be adapted according to local regulations and&#xD;
             guidelines for the administration of specific chemotherapies.&#xD;
&#xD;
          -  Ability to understand and sign a written informed consent document. Participant must&#xD;
             have willingness and ability to comply with scheduled visits, treatment plans,&#xD;
             laboratory tests and other study procedures.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant (see Appendix&#xD;
             1), not breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
          -  Not a woman of childbearing potential (WOCBP) as defined in Appendix 1 OR&#xD;
&#xD;
          -  A WOCBP who agrees to follow the contraceptive guidance in Appendix 1 during the&#xD;
             treatment period and for at least 120 days plus 30 days (a menstruation cycle) after&#xD;
             the last dose of study treatment.&#xD;
&#xD;
          -  Males who are sexually active with WOCBP must agree to follow instructions for&#xD;
             method(s) of contraception (see Appendix 1) for the duration of treatment with study&#xD;
             treatment(s) and for a total of 180 days posttreatment completion. In addition, male&#xD;
             participants must be willing to refrain from sperm donation during this time.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Borderline resectable, locally advanced or distant metastatic disease&#xD;
&#xD;
          -  Any medical condition which makes definitive surgical resection of the pancreatic&#xD;
             cancer contraindicated due to high risk of morbidity/mortality&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in past 2 years&#xD;
             (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive&#xD;
             drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency) is not considered a form&#xD;
             of systemic treatment.&#xD;
&#xD;
             4. Medical history and concurrent disease as below:&#xD;
&#xD;
             • Participants with a condition requiring systemic treatment with either&#xD;
             corticosteroids (&gt; 10 mg daily prednisone equivalents) or other immunosuppressive&#xD;
             medications within 14 days of study treatment administration except for adrenal&#xD;
             replacement steroid doses &gt; 10 mg daily prednisone equivalent in the absence of active&#xD;
             autoimmune disease.&#xD;
&#xD;
        Note: Treatment with a short course of steroids (&lt; 5 days) up to 7 days prior to initiating&#xD;
        study treatment is permitted. Participants with asthma that require intermittent use&#xD;
        intermittent use of bronchodilators, inhaled steroids, or local steroid injections would&#xD;
        not be excluded from the study.&#xD;
&#xD;
          -  Interstitial lung disease that is symptomatic or may interfere with the detection or&#xD;
             management of suspected treatment-related pulmonary toxicity.&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease including, but not limited to, any&#xD;
             of the following:&#xD;
&#xD;
               -  Myocardial infarction or stroke/transient ischemic attack within the past 6&#xD;
                  months&#xD;
&#xD;
               -  Uncontrolled angina within the past 3 months&#xD;
&#xD;
               -  Any history of clinically significant arrhythmias (such as ventricular&#xD;
                  tachycardia, ventricular fibrillation, or torsades de pointes)&#xD;
&#xD;
               -  History of other clinically significant heart disease (eg, cardiomyopathy,&#xD;
                  congestive heart failure with New York Heart Association functional&#xD;
                  classification III to IV, pericarditis, significant pericardial effusion, or&#xD;
                  myocarditis)&#xD;
&#xD;
               -  Cardiovascular disease-related requirement for daily supplemental oxygen therapy.&#xD;
&#xD;
          -  Evidence of uncontrolled, active infection, requiring parenteral or oral&#xD;
             anti-bacterial, anti-viral or anti-fungal therapy ≤ 28 days prior to screening on&#xD;
             study.&#xD;
&#xD;
          -  Participants with a condition requiring chronic systemic oral treatment with either&#xD;
             antibiotics or anti-fungals&#xD;
&#xD;
          -  Any uncontrolled inflammatory GI disease including Crohn's Disease and ulcerative&#xD;
             colitis.&#xD;
&#xD;
               -  Participants with active, known, or suspected autoimmune disease. Participants&#xD;
                  with vitiligo, type I diabetes mellitus, residual hypothyroidism due to&#xD;
                  autoimmune condition only requiring hormone replacement, euthyroid participants&#xD;
                  with a history of Grave's disease (participants with suspected autoimmune thyroid&#xD;
                  disorders must be negative for thyroglobulin and thyroid peroxidase antibodies&#xD;
                  and thyroid stimulating immunoglobulin prior to first dose of study treatment),&#xD;
                  psoriasis not requiring systemic treatment, or conditions not expected to recur&#xD;
                  in the absence of an external trigger are permitted to enroll after discussing&#xD;
                  with the Principal Investigator.&#xD;
&#xD;
               -  Has received a live vaccine within 30 days prior to the first dose of study drug.&#xD;
                  Examples of live vaccines include, but are not limited to, the following:&#xD;
                  measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies,&#xD;
                  Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines&#xD;
                  for injection are generally killed virus vaccines and are allowed; however,&#xD;
                  intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are&#xD;
                  not allowed. *Note: for those participants who will be undergoing planned&#xD;
                  splenectomy, vaccinations against S. pneumoniae, N. meningitidis, H. influenzae&#xD;
                  type b and influenza virus should be administered at least 2 weeks after the&#xD;
                  surgical intervention.&#xD;
&#xD;
               -  Known human immunodeficiency virus (HIV), known active hepatitis A, or known&#xD;
                  hepatitis B or C infection.&#xD;
&#xD;
               -  History of acute diverticulitis within the last 6 months or current chronic&#xD;
                  diarrhea&#xD;
&#xD;
               -  Expected to require any other form of antineoplastic or surgical therapy while on&#xD;
                  study&#xD;
&#xD;
               -  Pregnant or lactating women&#xD;
&#xD;
               -  A WOCBP who has a positive urine pregnancy test within 72 hours or no pregnancy&#xD;
                  test prior to registration (see Appendix 1). If the urine test is positive or&#xD;
                  cannot be confirmed as negative, a serum pregnancy test will be required.&#xD;
&#xD;
        Note: in the event that &gt;72 hours have elapsed between the screening pregnancy test and the&#xD;
        first dose of study treatment, another pregnancy test (urine or serum) must be performed&#xD;
        and must be negative in order for subject to start receiving study medication.&#xD;
&#xD;
          -  WOCBP who are unwilling or unable to use an acceptable method to minimize the risk of&#xD;
             pregnancy (see Appendix 1) for the entire study period and 120 days plus 30 days (a&#xD;
             menstruation cycle) after the last dose of study treatment. WOCBP who are continuously&#xD;
             not heterosexually active are also exempt from contraceptive requirements, but still&#xD;
             must undergo pregnancy testing as described in section 20.&#xD;
&#xD;
          -  Sexually active fertile men not using effective birth control if their partners are&#xD;
             WOCBP&#xD;
&#xD;
          -  History of primary immunodeficiency&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis.&#xD;
&#xD;
          -  History of organ allograft or allogeneic bone marrow transplant.&#xD;
&#xD;
          -  Any prior radiation therapy, immunotherapy, or biologic ('targeted') therapy for&#xD;
             treatment of the patient's pancreatic tumor. Biliary stent is allowed.&#xD;
&#xD;
          -  Treatment for other invasive carcinomas within the last two years who are at greater&#xD;
             than 5% risk of recurrence at time of eligibility screening. Carcinoma in-situ and&#xD;
             basal cell carcinoma/ squamous cell carcinoma of the skin are allowed.&#xD;
&#xD;
          -  Participation in any investigational drug study within 4 weeks preceding the start of&#xD;
             study treatment.&#xD;
&#xD;
          -  Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment,&#xD;
             without complete recovery.&#xD;
&#xD;
          -  History of allergy to study treatments or any of its components&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deidre Cohen</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Langone Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>Upon reasonable request. Requests should be directed to Kirsten.Swingle@nyulangone.org. To gain access, data requestors will need to sign a data access agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

